Skip to main content
Clinical Trials/NCT00000236
NCT00000236
Completed
Phase 2

Buprenorphine Pharmacology Related to Addiction Treatment

National Institute on Drug Abuse (NIDA)1 site in 1 countrySeptember 21, 1999

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Opioid-Related Disorders
Sponsor
National Institute on Drug Abuse (NIDA)
Locations
1
Primary Endpoint
Drug use
Status
Completed
Last Updated
20 years ago

Overview

Brief Summary

The purpose of this study is to examine the interactions between buprenorphine and naltrexone, and to assess how they may directly impact the clinical issues involving: transferring patients from buprenorphine to naltrexone, developing a non-abusable form of buprenorphine, and enhancing patient acceptability of naltrexone.

Registry
clinicaltrials.gov
Start Date
September 21, 1999
End Date
TBD
Last Updated
20 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Drug use

Opioid agonist effects

Opiate withdrawal

Psychological changes in: pupil diameter, blood pressure, heart rate, respiration

Study Sites (1)

Loading locations...

Similar Trials